Carrato, ABenavides, MMassuti, BFerreiro-Monteagudo, RGarcia Alfonso, PilarFalcó, EstherReboredo, MCano, TGallego, JavierVieitez, JMLayos, LSalud, APolo, EDotor, EmmaDuran-Ogalla, GRodriguez-Garrote, MCalvo, AGrande, EAranda, E2024-09-102024-09-102019-06-03Carrato A, Benavides M, Massuti B, Ferreiro-Monteagudo R, Garcia Alfonso P, Falcó E, et al. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC Cancer. 2019 Jun 03;19:533.1471-2407http://hdl.handle.net/20.500.13003/16364https://hdl.handle.net/20.500.12105/22655Background: Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC. Methods: Frail patients without prior advanced colorectal cancer treatment were included in the study. Definition of frailty was defined per protocol based on dependency criteria, presence of chronic comorbid pathologies and/or geriatric features. Main objective: to assess progression-free survival (PFS) rate at 6 months. Treatment consisted of 28-daycycles of orally administered regorafenib 160mg/day (3 weeks followed by 1 week rest).ResultsForty-seven patients were included in the study. Median age was 81years (range 63-89). Frailty criteria: dependency was observed in 26 patients (55%), comorbidities in 27 (57%) and geriatric features in 18 (38%). PFS rate at 6months was 45% (95% confidence interval [CI] 30-60]. Median PFS was 5.6months (95%CI 2.7-8.4). Median overall survival (OS) was 16months (95%CI 7.8-24). Complete response, partial response and stable disease were observed in one, two and 21 patients respectively (objective response rate 6.4%; disease control rate 51%). Thirty-nine patients (83%) experienced grade 3-4 adverse events (AEs). The most common grade 3-4 AEs were hypertension (15 patients; 32%), asthenia (14; 30%), hypophosphatemia (6; 13%); diarrhea (4; 8%), hand-foot-skin reaction (4; 8%). There were two toxic deaths (4.2%) (grade 5 rectal bleeding and death not further specified). Dose reduction was required in 26 patients (55%) and dose-delays in 13 patients (28%). Conclusions: The study did not meet the pre-specified boundary of 55% PFS rate at 6months. Toxicity observed (83% patients experienced grade 3 and 4 AEs) preclude its current use in clinical practice on this setting. Disease control rate and overall survival results are interesting and might warrant further investigation to identify those who benefit from this approach.Trial registration: This trial was prospectively registered at EudraCT (2013-000236-94). Date of trial registration: April 9th, 2013.enghttp://creativecommons.org/licenses/by/4.0/RegorafenibColorectal cancerMonotherapyFirst-lineFrail patientsElderlyresearch articleAttribution 4.0 International311597651953310.1186/s12885-019-5753-7BMC Canceropen accessHipofosfatemiaSupervivencia sin ProgresiónResultado del TratamientoNeoplasias ColorrectalesFemeninoMetástasis de la NeoplasiaMasculinoEstudios de SeguimientoAdministración OralHipertensiónPiridinasProyectos PilotoRelación Dosis-Respuesta a DrogaHumanosPersona de Mediana EdadAsteniaAncianoAnciano de 80 o más AñosCompuestos de FenilureaEspañaAnciano Frágil2-s2.0-85066863564470106800002L627947542